smpСкорая медицинская помощьEMERGENCY MEDICAL CARE2072-6716Northwest State Medical University named after II Mechnikov10.24884/2072-6716-2019-20-2-67-73smp-343Research ArticleОБЗОРЫREVIEWSОСТРЫЙ КОРОНАРНЫЙ СИНДРОМ: ЧТО ИЗМЕНИЛОСЬ В НАШИХ ПРЕДСТАВЛЕНИЯХ О ПАТОГЕНЕЗЕ И ПОДХОДАХ К ЛЕЧЕНИЮ? (ЧАСТЬ I)ACUTE CORONARY SYNDROME: A SEA CHANGE IN OUR UNDERSTANDING OF PATHOGENESIS AND WAY OF TREATMENT? (PART I)ШальневВ. И.ShalnevV. I.

Шальнев Владимир Ильич — доктор медицинских наук, профессор кафедры скорой медицинской помощи

191015, Санкт-Петербург, Кирочная ул., д. 41 

Vladimir I. Shalnev   

St. Petersburg

Visszgmu@yandex.ruСеверо-Западный государственный медицинский университет им. И. И. МечниковаРоссияNorth-Western State Medical University named after I. I. MechnikovRussian Federation2019040620192026773Copyright © Шальнев В.И., 20192019Шальнев В.И.Shalnev V.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://smp.spb.ru/jour/article/view/343

В статье освещаются роль воспалительных факторов в патогенезе атеротромбоза и концепция резидуального воспалительного риска у больных ИБС. Анализируются результаты ряда крупных международных клинических исследований, посвященных роли различных противовоспалительных средств в лечении ИБС, проведенных в последние годы. Обсуждаются возможности и перспективы применения иммуномодулирующих и противовоспалительных средств в терапии острого коронарно­го синдрома.  

The article highlights the hypothesis of the inflammatory pathways in pathogenesis of atherothrombosis and the conception of residual inflammatory risk in coronary heart disease patients. Modern approach to the correction of inflammatory risk by immune-modulating therapy in acute coronary syndrome setting is discussed. The results of most significant randomized clinical trials dedicated to this problem are also highlighted.  

острый коронарный синдроматеротромбозвоспалениеacute coronary syndromeatherothrombosisinflammationReferencesКардиоваскулярная профилактика 2017. Российские национальные рекомендации// Российский кардиологический журнал. 2018. Т. 23, № 6. С. 7–122Kardiovaskularnaya profilaktika 2017. Rossiyskie natsionalnie rekomendatsii. Rossiyskiy kardiologicheskiy jurnal, 2018, vol. 23, No 8, pp. 7–122 (in Russ.).Townsend N., Wilson L., Bhatnagar P. et al. Cardiovascular disease in Europe: epidemiological update 2016 // Eur. Heart J. 2016. Vol. 37 (42). P. 3232–3245.Townsend N., Wilson L., Bhatnagar P. et al. Cardiovascular disease in Europe: epidemiological update 2016 // Eur. Heart J. 2016. Vol. 37 (42). P. 3232–3245.Roffi M., Patrono C., Collet J. P. et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology // Eur. Heart J. 2016. Vol. 37 (3). P. 267–315.Roffi M., Patrono C., Collet J. P. et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology // Eur. Heart J. 2016. Vol. 37 (3). P. 267–315.Ibanez B., Agawall S., Antunes M. et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology // Eur. Heart J. 2018. Vol 39. P. 119–177.Ibanez B., Agawall S., Antunes M. et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology // Eur. Heart J. 2018. Vol 39. P. 119–177.Gale C.P., Allan V., Cattle B. A. et al. Trends in hospital treatments, including revascularisation, following acute myocardial infarction, 2003–2010: a multilevel and relative survival analysis for the National Institute for Cardiovascular Outcomes Research (NICOR) // Heart. 2014. Vol. 100 (7). P. 582–589.Gale C.P., Allan V., Cattle B. A. et al. Trends in hospital treatments, including revascularisation, following acute myocardial infarction, 2003–2010: a multilevel and relative survival analysis for the National Institute for Cardiovascular Outcomes Research (NICOR) // Heart. 2014. Vol. 100 (7). P. 582–589.Valgimigli M., Bueno H., Byrne R. et al. 2017 ESC Focused Update on Dual Antiplatelet Therapy in Coronary Artery Disease in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). The Task Force for the Management of Dual Antiplatelet Therapy in Coronary Artery Disease of the European Society of Cardiology // Eur. Heart J. 2018. Vol. 39. P. 213–260.Valgimigli M., Bueno H., Byrne R. et al. 2017 ESC Focused Update on Dual Antiplatelet Therapy in Coronary Artery Disease in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). The Task Force for the Management of Dual Antiplatelet Therapy in Coronary Artery Disease of the European Society of Cardiology // Eur. Heart J. 2018. Vol. 39. P. 213–260.Caggegi A., Capodanno D., Capranzano P. et al. Comparison of one-year outcomes of percutaneous coronary intervention versus coronary artery bypass grafting in patients with unprotected left main coronary artery disease and acute coronary syndromes (from the CUSTOMIZE Registry) // Am. J. Cardiol. 2011. Vol. 108 (3). P. 355–359.Caggegi A., Capodanno D., Capranzano P. et al. Comparison of one-year outcomes of percutaneous coronary intervention versus coronary artery bypass grafting in patients with unprotected left main coronary artery disease and acute coronary syndromes (from the CUSTOMIZE Registry) // Am. J. Cardiol. 2011. Vol. 108 (3). P. 355–359.Tang E.W., Wong C. K., Herbison P. et al. Global Registry of Acute Coronary Events (GRACE) hospital discharge risk score accurately predicts long-term mortality post acute coronary syndrome // Am. Heart J. 2007. Vol. 153. P. 29–35.Tang E.W., Wong C. K., Herbison P. et al. Global Registry of Acute Coronary Events (GRACE) hospital discharge risk score accurately predicts long-term mortality post acute coronary syndrome // Am. Heart J. 2007. Vol. 153. P. 29–35.Ridker P. M. Residual inflammatory risk: addressing the obverse side of the atherosclerosis prevention coin // Eur. Heart J. 2016. Vol. 37. P. 1720–1722.Ridker P. M. Residual inflammatory risk: addressing the obverse side of the atherosclerosis prevention coin // Eur. Heart J. 2016. Vol. 37. P. 1720–1722.Ross R. Atherosclerosis — an inflammatory disease // N. Engl. J. Med. 1999. Vol. 340. P. 115–126Ross R. Atherosclerosis — an inflammatory disease // N. Engl. J. Med. 1999. Vol. 340. P. 115–126Libby P., Ridker P. M., Hansson G. K. Inflamation in atherosclerosis: from pathophysiology to practice // J. Am. Coll. Cardiol. 2009. Vol. 54. P. 2129–2138.Libby P., Ridker P. M., Hansson G. K. Inflamation in atherosclerosis: from pathophysiology to practice // J. Am. Coll. Cardiol. 2009. Vol. 54. P. 2129–2138.Кухтина Н.Б, Арефьева Т. И., Арефьева А.М и др. Экспрессия цитокинов и хемокинов в атеросклеротических бляшках и внутренней оболочке артерий у больных ИБС // Терапевтический архив. 2008. № 4. С. 63– 69.Kuhtina N. B., Arefieva T. I., Arefieva A. M. et al. Ekspressiya citokinov I hemokinov v ateroskleroticheskih blyashkah I vnutrenney obolochke arteriy u bolnich IBC. Terapevticheskiy arhiv, 2008, No 4, pp. 63– 69 (in Russ.).Рагино Ю. И., Чернявский А. М., Полонская Я. В. и др. Содержание провоспалительных цитокинов, хемоаттрактантов и деструктивных металлопротеиназ в разных типах нестабильных атеросклеротических бляшек // Атеросклероз и дислипидемии. 2011. № 1. С. 23–27Ragino Y. I., Chernyavskiy A. M., Polonskaya Y. V. et al. Soderjanie provospalitelnich citokinov, hemoattraktantov I destruktivnich metalloproteinaz v raznih tipah ateroskleroticheskih blyashek. Ateroskleroz I dislipidemii, 2011, No 1, pp. 23– 27 (in Russ.).Рагино Ю.И., Волков А. М., Чернявский А. М. и др. Стадии развития атеросклеротического очага и типы нестабильных бляшек — патофизиологическая и гистологическая характеристика // Российский кардиологический журнал. 2013. № 8. С. 88–95.Ragino Y. I., Volkov A. M., Chernyavskiy A. M. et al. Stadii razvitiya ateroskleroticheskogo ochaga I tipi nestabilnich blyashek – patofiziologicheskaya I gistologicheskaya harakteristika. Rossiyskiy kardiologicheskiy jurnal, 2013, No 8, pp. 23–27 (in Russ.)Frangogiannis N. G. Regulation of inflammatory response in cardiac repair // Circulation Res. 2012. Vol. 110. P. 159–173.Frangogiannis N. G. Regulation of inflammatory response in cardiac repair // Circulation Res. 2012. Vol. 110. P. 159–173.O’Donoghue M.L., Braunwald E., White H. D. et al. Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial // JAMA. 2014. Vol. 312. P. 1006–1015.O’Donoghue M.L., Braunwald E., White H. D. et al. Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial // JAMA. 2014. Vol. 312. P. 1006–1015.Kitsis R., Jialal I. Limiting Myocardial Damage during Acute Myocardial Infarction by Inhibiting C-Reactive Protein // N. Engl. J. Med. 2006. Vol. 355. P. 513–516.Kitsis R., Jialal I. Limiting Myocardial Damage during Acute Myocardial Infarction by Inhibiting C-Reactive Protein // N. Engl. J. Med. 2006. Vol. 355. P. 513–516.Kleveland O., Kunst G., Bratlie M. et al. Effect of a single dose of the interleukin 6 receptor antagonist tocilizumab on inflammation and troponin T release in patients with non-ST-elevation myocardial infarction: a double-blind, randomized, placebo-controlled phase 2 trial // Eur. Heart J. 2016. Vol. 30. P. 2406–2413.Kleveland O., Kunst G., Bratlie M. et al. Effect of a single dose of the interleukin 6 receptor antagonist tocilizumab on inflammation and troponin T release in patients with non-ST-elevation myocardial infarction: a double-blind, randomized, placebo-controlled phase 2 trial // Eur. Heart J. 2016. Vol. 30. P. 2406–2413.O’Donoghue M.L., Glaser R., Cavender M. A. et al. Effect of losmapimod on cardiovascular outcomes in patients hospitalized with acute myocardial infarction: a randomized clinical trial // JAMA. 2016. Vol. 315. P. 1591– 1599.O’Donoghue M.L., Glaser R., Cavender M. A. et al. Effect of losmapimod on cardiovascular outcomes in patients hospitalized with acute myocardial infarction: a randomized clinical trial // JAMA. 2016. Vol. 315. P. 1591– 1599.Шальнев В. И. Роль воспалительных факторов в патогенезе атеросклеротического поражения сосудов // Российский семейный врач. 2005. № 3. С. 4–11.Shalnev V. I. Rol vospalitelnich faktorov v patogeneze aterosleroticheskogo porajeniya sosudov. Rossiyskiy semeiyniy vrach, 2005, No 3, pp. 4–11 (in Russ.).Shalnev V. I. Mazurov V. I., Miroshnichenko A. G. The Early Start of Statin Therapy Reduces the Level of CRP and the Rate of post-AMI Angina // Acute Cardiac Care. 2006. Vol. 8 (Suppl. 2). Р. 139–140.Shalnev V. I. Mazurov V. I., Miroshnichenko A. G. The Early Start of Statin Therapy Reduces the Level of CRP and the Rate of post-AMI Angina // Acute Cardiac Care. 2006. Vol. 8 (Suppl. 2). Р. 139–140.Шальнев В. И. Влияние раннего применения симвастатина на уровень С-реактивного белка, липиды крови и клиническое течение при остром коронарном синдроме // Клиническая медицина. 2007. № 11. С. 46–50.Shalnev V. I. Vliyanie rannego primeneniya simvastatina na uroven C-reaktivnogo belka, lipidi krovi i klnicheskoe techenie pri ostrom koronarnom sindrome. Klinicheskaya meditsina, 2007, No 11, pp. 46– 50 (in Russ.).Шальнев В.И., Мазуров В.И Особенности динамики медиаторов воспаления при остром коронарном синдроме. Роль терапии статинами // Кардиоваскулярная терапия и профилактика. 2007. № 6. С. 338– 339.Shalnev V. I., Mazurov V. I. Osobennosti dinamiki mediatorov vospaleniya pri ostrom koronarnom syndrome. Rol terapii statinami. Kardiovaskularnaya terapiya I profilaktika, 2007, No 6, pp. 338– 339 (in Russ.).Шальнев В.И., Мазуров В. И. Маркеры воспаления при остром коронарном синдроме: Роль в патогенезе и прогностическое значение // Скорая медицинская помощь. 2012. № 2. С. 70–76.Shalnev V. I., Mazurov V. I. Markeri vospaleniya pri ostrom koronarnom syndrome: rol v patogeneze I prognosticheskoe znachenie. Skoraya meditsinskaya pomosh, 2012, No 2, pp. 70–76 (in Russ.).Ridker P., MacFadyen J.G., Everett B. M. et al. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomized controlled trial // Lancet. 2018. Vol. 391. P. 319–328.Ridker P., MacFadyen J.G., Everett B. M. et al. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomized controlled trial // Lancet. 2018. Vol. 391. P. 319–328.Ridker P.M., Libby P., MacFadyen J.G. et al. Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS) // Eur. Heart J. 2018. Vol. 39. P. 3499–3507.Ridker P.M., Libby P., MacFadyen J.G. et al. Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS) // Eur. Heart J. 2018. Vol. 39. P. 3499–3507.Sager H.B., Heidt T., Hulsmans M. et al. Targeting interleukin-1β reduces leukocyte production after acute myocardial infarction // Circulation. 2015. Vol. 132. P. 1880–1890.Sager H.B., Heidt T., Hulsmans M. et al. Targeting interleukin-1β reduces leukocyte production after acute myocardial infarction // Circulation. 2015. Vol. 132. P. 1880–1890.Morton A.C, Rothman A. M., Greenwood J. P. et al. The effect of interleukin-1 receptor antagonist therapy on markers of inflammation in non-ST elevation acute coronary syndromes: the MRC–ILA Heart Study // Eur. Heart J. 2015. Vol. 36. P. 377–384.Morton A.C, Rothman A. M., Greenwood J. P. et al. The effect of interleukin-1 receptor antagonist therapy on markers of inflammation in non-ST elevation acute coronary syndromes: the MRC–ILA Heart Study // Eur. Heart J. 2015. Vol. 36. P. 377–384.Van Tassell B., Toldo S., Mezzaroma E. Targeting interleukin-1 in heart disease // Circulation. 2013. Vol. 128. P. 1910–1923.Van Tassell B., Toldo S., Mezzaroma E. Targeting interleukin-1 in heart disease // Circulation. 2013. Vol. 128. P. 1910–1923.The Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R MR) Consortium. The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis // Lancet. 2012. Vol. 379. P. 1214–1224.The Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R MR) Consortium. The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis // Lancet. 2012. Vol. 379. P. 1214–1224.Ridker P. M. From C-reactive protein to interleukin-6 to interleukin-1: moving upstream to identify novel targets for atheroprotection // Circulation Res. 2016. Vol. 118. P. 145–156.Ridker P. M. From C-reactive protein to interleukin-6 to interleukin-1: moving upstream to identify novel targets for atheroprotection // Circulation Res. 2016. Vol. 118. P. 145–156.Шальнев В. И. Динамика содержания интерлейкина-6 в плазме крови больных острым коронарным синдромом // Скорая медицинская помощь. 2011. № 1. С. 75–80.Shalnev V. I. Dinamika soderjaniya interleykina-6 v plasme krovi bolnih ostrim koronarnim sindromom. Skoraya meditsinskaya pomosh, 2011, No 1, pp. 75– 80 (in Russ.).Ridker P., Everett B., Pradhan M. et al. for the CIRT investigators. Low-Dose Methotrexate for the Prevention of Atherosclerotic Events // New Engl. J. Med. 2018. Nov. 10 (Epub ehead of print).Ridker P., Everett B., Pradhan M. et al. for the CIRT investigators. Low-Dose Methotrexate for the Prevention of Atherosclerotic Events // New Engl. J. Med. 2018. Nov. 10 (Epub ehead of print).Weber C., von Hundelshausen P. CANTOS trial validates the inflammatory pathogenesis of atherosclerosis: setting the stage for a new chapter in therapeutic targeting // Circulaton Res. 2017. Vol. 121. P. 1119–1121.Weber C., von Hundelshausen P. CANTOS trial validates the inflammatory pathogenesis of atherosclerosis: setting the stage for a new chapter in therapeutic targeting // Circulaton Res. 2017. Vol. 121. P. 1119–1121.

The authors declare that there are no conflicts of interest present.